How Bayer Makes Decisions to Develop New Drugs

References

• Balthasar H. U., Boschi R. A. A., Menke M. M. Calling the shots in R&D. Harvard Bus. Rev. (1978) 56(May-June):151–160Google Scholar
• Bodily S. E., Allen M. S. A dialogue process for choosing value-creating strategies. Interfaces (1999) 29(6):16–28Link, Google Scholar
• Boschi R. A. A., Balthasar H. U., Menke M. M. Quantifying and forecasting exploratory research success. Res. Management (1979) 22(5):14–21Google Scholar
• DiMasi J. A. New drug development: Cost, risk, and complexity. Drug Information J (1995) 29(2):375–384Crossref, Google Scholar
• Grabowski H., Vernon J. Returns to R&D on new drug introductions in the 1980s. J. Health Econom. (1994) 13(4):383–406Crossref, Google Scholar
• Halliday R. G., Walker S. R., Lumley C. E. R&D philosophy and management in the world's leading pharmaceutical companies. J. Pharm. Med. (1992) 2(3):139–154Google Scholar
• Keefer D. L. Facilities evaluation under uncertainty: Pricing a refinery. Interfaces (1995) 25(6):57–66Link, Google Scholar
• Keefer D. L., Bodily S. E. Three-point approximation for continuous randomvariables. Management Sci. (1983) 29(5):595–609Link, Google Scholar
• Keeney R.Value-Focused Thinking (1992) (Harvard University Press, Cambridge, MA) Google Scholar
• Merkhofer M. W. Quantifying judgmental uncertainty: Methodology, experiences, and insights. IEEE Trans. Systems, Man, Cybernetics (1987) SMC-17(5):741–752Crossref, Google Scholar
• Neudeck B. L., Blumenschein K., Endean E. D., Loh F. K., Rapp R. P. Intra-arterial urokinase versus surgery for acute peripheral arterial occlusion. Amer. J. Health-System Pharm. (1997) 54(17):1963–1968Crossref, Google Scholar
• Ouriel K., Veith F. J., Sasahara A. A. Thrombolysis on peripheral arterial surgery: Phase I results. J. Vascular Surgery (1996) 23(1):64–73Crossref, Google Scholar
• Ouriel K., Veith F. J., Sasahara A. A. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. New England J. Medicine (1998) 338(16):1105–1111Crossref, Google Scholar
• Poland W. B. Simple probabilistic evaluation of portfolio strategies. Interfaces (1999) 29(6):75–83Link, Google Scholar
• Schmidt R. L. A stochastic optimization model to improve production planning and R&D resource allocation in biopharmaceutical production processes. Management Sci. (1996) 42(4):603–617Link, Google Scholar
• Shephard G. G., Kirkwood C. W. Managing the judgmental probability elicitation process: A case study of analyst/manager interaction. IEEE Trans. Engrg. Management (1994) 41(4):414–425Crossref, Google Scholar
• Spetzler C. S., Staël von Holstein C.-A. S. Probability encoding in decision analysis. Management Sci. (1975) 22(3):340–352Link, Google Scholar
• STILE Investigators Results of a prospective randomised trial evaluating surgery versus thrombolysis for ischaemia of the lower extremity. Ann. Surgery (1994) 220(3):251–266Crossref, Google Scholar
• Struck M. M. Biopharmaceutical R&D success rates and development times. Bio/Technology (1994) 12(July):674–677Crossref, Google Scholar
• Tiggemann R. F., Dworaczyk D. A., Sabel H. Project portfolio management: A powerful strategic weapon in pharmaceutical drug development. Drug Information J. (1998) 32(3):813–824Crossref, Google Scholar